BCHE and Alzheimer disease: Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), which catalyze breakdown of the neurotransmitter acetylcholine in cholinergic synapses, are currently the most viable therapeutic targets for symptomatic treatment of AD.